What's in McNeil AB's pipeline?

McNeil AB has 12 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 8 in Phase 1.

Which companies overlap with McNeil AB's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/mcneil-ab.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

McNeil AB pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 8 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area
Placebo gum	Placebo gum	marketed
Pseudoephedrine/Paracetamol	Pseudoephedrine/Paracetamol	marketed	Decongestant/analgesic combination	Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)	Cold and Flu Symptom Relief
Nasic	Nasic	phase 3			Other

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for McNeil AB:

Drug Landscape (2026). McNeil AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mcneil-ab. Accessed 2026-05-13.